Ansari HR, Nadeem A, Tilley SL, Mustafa SJ. Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta. Am J Physiol Heart Circ Physiol 293: H3448-H3455, 2007. First published October 5, 2007; doi:10.1152/ajpheart.00764.2007.-We investigated whether A 3 adenosine receptor (A 3 AR) is involved in endothelium-mediated contraction through cyclooxygenases (COXs) with the use of wild-type (WT) and A 3 knockout (A3KO) mice aorta. A3AR-selective agonist, Cl-IBMECA, produced a concentration-dependent contraction (EC 50: 2.9 Ϯ 0.2 ϫ 10 Ϫ9 M) in WT mouse aorta with intact endothelium (ϩE) and negligible effects in A 3KO ϩE aorta. At 10 Ϫ7 M, contractions produced by Cl-IBMECA were 29% in WT ϩE, while being insignificant in A 3KO ϩE aorta. Cl-IBMECA-induced responses were abolished in endothelium-denuded tissues (ϪE), in both WT and A3KO aorta. A 3 AR gene and protein expression were reduced by 74 and 72% (P Ͻ 0.05), respectively, in WT ϪE compared with WT ϩE aorta, while being undetected in A 3 KO ϩE/ϪE aorta. Indomethacin (nonspecific COXs blocker, 10 Ϫ5 M), SC-560 (specific COX-1 blocker, 10 Ϫ8 M), SQ 29549 (thromboxane prostanoid receptor antagonist, 10 Ϫ6 M), and furegrelate (thromboxane synthase inhibitor, 10 Ϫ5 M) inhibited Cl-IBMECA-induced contraction significantly. Cl-IBMECA-induced thromboxane B2 production was also attenuated significantly by indomethacin, SC-560, and furegrelate in WT ϩE aorta, while having negligible effects in A 3KO ϩE aorta. NS-398 (specific COX-2 blocker) produced negligible inhibition of Cl-IBMECA-induced contraction in both WT ϩE and A 3KO ϩE aorta. Cl-IBMECA-induced increase in COX-1 and thromboxane prostanoid receptor expression were significantly inhibited by MRS1523, a specific A 3AR antagonist in WT ϩE aorta. Expression of both A 3AR and COX-1 was located mostly on endothelium of WT and A 3KO ϩE aorta. These results demonstrate for the first time the involvement of COX-1 pathway in A3AR-mediated contraction via endothelium.
ADENOSINE IS A UBIQUITOUS endogenous substance, which is involved directly or indirectly in regulating the vascular tone (35) . The physiological effects of adenosine are mediated by activation of cell surface adenosine receptors (ARs). Four subtypes of receptors, namely A 1 , A 2A , A 2B , and A 3 ARs, are known so far whose vascular effects vary with the receptor subtype. The A 3 AR is the most recently identified subtype and is negatively coupled to adenylate cyclase, similar to A 1 AR (16) .
The role of ARs in aortic contraction and relaxation has been studied in several species earlier. A 2B AR and A 2A AR have been shown to have vasorelaxant, whereas A 1 AR has been shown to have vasoconstrictive properties in mice and rats (1, 18, 36, 37) . However, the role of A 3 AR has not been studied in mice aorta, although its protective role in ischemia-reperfusion injury in the heart has been defined earlier (15) . A 3 AR activation in one study has been shown to cause vasoconstriction in hamster arterioles (30) ; however, it was not explored whether this response was endothelium dependent or independent.
Endothelial-derived mediators play an important role in modulating vascular tone. In vascular diseases, such as hypertension and diabetes, the endothelial cells become dysfunctional, which is characterized by reduced release of endothelial-derived relaxing factors (13, 39) or increased release of contractile mediators (17, 29) . Endothelium-dependent contractions are mediated by products of cyclooxygenases (COXs), because blockers of these enzymes, such as indomethacin, have been shown to inhibit contractile response in vessels (40) . COXs modulate biological and pathological processes primarily through their active metabolites, namely prostaglandin (PG) E 2 , PGI 2 , thromboxane (Tx) A 2 , PGF 2␣ , and PGD 2 (5, 32) . These prostanoids diffuse to the smooth muscle and activate Tx prostanoid (TP) receptors, finally causing contraction in a variety of tissues (8, 41) . However, the pathway accounting for endothelium-dependent contraction in relation to A 3 AR is not well understood.
COXs catalyze the synthesis of PGs from arachidonic acid, and two isozymes encoded by different genes, COX-1 and COX-2, mediate this process (14, 32) . Accumulating evidence indicates that COX-1 and COX-2 activities differentially influence the renal and cardiovascular functions (6, 26, 34, 42) . It has been shown in various studies that COX-1, being a constitutive enzyme, is primarily responsible for basal prostanoid production in the aorta (27) , whereas COX-2, being an inducible enzyme, may be more important under inflammatory/ disease conditions (7) . The present study is a further step in exploring the contribution of each of these COX isoforms in mice aorta and their relationship with A 3 AR. Therefore, we have used A 3 AR agonists/antagonists and COX blockers, such as indomethacin (a nonspecific COX blocker), SC-560 (specific COX-1 blocker), NS-398 (specific COX-2 blocker), SQ 29548 (TP receptor antagonist), and furegrelate [Tx synthase (TS) inhibitor] to elucidate the role of COX-1/COX-2 in A 3 AR-mediated aortic contraction. Our results indicate that both A 3 AR and COX-1 are mostly expressed on endothelium, where the activation of A 3 AR leads to endothelium-dependent contraction and TxB 2 production, mainly via COX-1 in wildtype (WT) mice, while being absent in A 3 knockout (KO) mice aorta.
MATERIALS AND METHODS
All of the experimental protocols were performed according to the guidelines and approval of the Animal Care and Use Committee at West Virginia University. A 3KO mice were generated, as previously described (28) and backcrossed 12 generations to the Balb/C background. The corresponding WT (Balb/C) mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN) .
Preparation of isolated mouse aorta. A 3KO and their corresponding WT mice (10 -12 wk old) were used in this study. The mice were killed by deep anesthesia with pentobarbital sodium (100 mg/kg ip) followed by thoracotomy. Then the aorta was gently removed and cleaned of fat and connective tissue. The aorta was cut transversely into four rings that measured ϳ3-4 mm in length. Extreme care was taken not to damage the endothelium in the rings. In some rings, the endothelium was removed mechanically by placing a piece of thin wire in the lumen and rubbing the aortic ring. The rings were mounted vertically between two wire hooks. Rings were then suspended in 10-ml organ baths containing Krebs-Henseleit buffer. The KrebsHenseleit buffer (pH 7.4), containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO 4, 1.2 mM KH2PO4, 25 mM NaHCO3, 11 mM glucose, and 2.5 mM CaCl2, was maintained at 37°C with continuous bubbling of 95% O2 and 5% CO2. The aortic rings were equilibrated for 90 min with a resting force of 1 g, with changes of the bathing solution at 15-min interval.
Isometric force measurement. For measurement of isometric force response, the tissues were allowed to equilibrate for 90 min. The resting force of 1 g has been used in our laboratory earlier in mouse thoracic aorta (1, 36) . At the end of the equilibration period, the tissues were contracted with 50 mM KCl to check the viability of individual aortic rings. The rings were washed with Krebs-Hanseleit buffer and were constricted with phenylephrine (PE, 10 Ϫ7 M) for pharmacological studies. The changes in tension were monitored continuously with the fixed range precision force transducer connected to the differential amplifier (BIOPAC system). The data were recorded on a digital acquisition system and analyzed using Acknowledge 3.5.7 software (BIOPAC system).
Contraction experiments. The tissues were contracted with PE (10 Ϫ7 M) to produce consistent submaximal (ϳ90%) response in our experiments. The integrity of the vascular endothelium was assessed pharmacologically by acetylcholine (10 Ϫ7 M) to produce relaxation of PE precontracted rings. The tissues that did not elicit reproducible and stable contraction with PE (10 Ϫ7 M) and relax Ͻ50% with acetylcholine (10 Ϫ7 M) were discarded from the study. The endotheliumdenuded aortic rings showed no relaxation response to acetylcholine. The aortic rings were then washed several times with Krebs-Hanseleit buffer and allowed to equilibrate for 30 min before the experimental protocol began. In experiments where the involvement of endothelium was investigated, endothelium was removed using a thin stainless steel wire.
Experimental protocol. The concentration-response curves (CRCs) for agonists, Cl-IBMECA and CCPA, were run in parallel in aortic rings from both WT and A 3KO mice. In all of the cases, agonists were added in a cumulative fashion to yield the CRCs. In the experiments where the effects of antagonist were measured, it was added 30 min before contraction of the tissue with PE and was present throughout the experiment. Contractile responses were expressed as a percent increase in the contraction with respect to PE in response to each concentration of agonist used.
Real-time PCR: A 3AR and COX-1 genes expression. The isolation of total RNA from the mouse aortic tissue with and without endothelium was performed as described previously by our laboratory (1) . Briefly, the aortic tissues were homogenized using the TRIzol reagent followed by DNase treatment. This was followed by conversion of 0.5 g of total RNA into cDNA using high-capacity cDNA archive kit (Applied Biosystems) in a total volume of 100 l. The real-time PCR was performed using ABI PRISM 7300 Detection System (Applied Biosystems) using Taqman Universal Mastermix (Applied Biosystems, Branchburg, NJ). The reaction volume (25 l) included 12.5 l of 2ϫ Taqman Universal Mastermix, 1 l of cDNA, and 1.25 l of 20ϫ FAM-labeled Taqman gene expression assay master mix solution. For the real-time PCR of the A 3AR and COX-1 genes, the Taqman inventoried gene expression products were purchased from Applied Biosystems (Foster City, CA). The 18S rRNA (ribosomal RNA) was used as an endogenous control. The fold difference in expression of target cDNA was determined using the comparative threshold cycle (C T) method. The ⌬CT value was determined in each experiment by subtracting the average 18S C T value from the corresponding average C T for A3AR and COX-1 in aorta, with and without endothelium. The fold difference in gene expression of the target was calculated as described earlier (22) .
Measurement of TxB 2 levels. TxB2 levels were measured according to the method of Thakali et al. (38) , with little modification using an enzyme immunoassay (EIA) kit (Cayman Chemicals, Ann Arbor, MI). In brief, cleaned mice aorta were incubated at 37°C for 90 min in 1 ml of Krebs-Henseleit buffer, as described for organ bath studies. After incubation, tissues were treated with agonist/anatagonist, and incubation continued as indicated. The incubations were stopped by placing the aortic tissues in microfuge tubes on dry ice. TxB 2 (a stable TxA2 metabolite) was measured in the aortic tissues using the kit.
The tubes containing aortic tissues were thawed and homogenized in EIA buffer, followed by centrifugation for 30 min at 14,000 rpm. Supernatant (50 l) was added to a secondary antibody-coated 96-well plate to determine the amount of TxB2 present in each sample. A standard TxB2 curve was also performed (described under Data analysis). The total protein was determined by Bradford protein assay. TxB2 levels were normalized to total protein in each sample and expressed as picograms per milligram protein.
Western blotting: A3AR, COX-1, and TP receptor proteins expression. The aortic tissues [intact endothelium (ϩE)] from both WT and A3KO mice were homogenized in the lysis buffer (pH 8) containing 50 mM Tris ⅐ HCl, 40 mM Na4P2O7, 50 mM NaF, 5 mM MgCl2, 0.1 mM Na3VO4, 10 mM EGTA, 2 mM PMSF, 1% Triton X-100, aprotinin (10 g/ml), and leupeptin (10 g/ml). In the experiments where A3AR-mediated modulation in COX-1 and TP receptor expression was to be assessed, the aortic tissues (ϩE) from both WT and A3KO mice were processed similar to the organ bath experiments and treated with and without A3AR agonist (Cl-IBMECA, 10 Ϫ7 M). For measurements of COX-1 and TP receptor expressions by Western blotting, anti-COX-1 and -TP receptor polyclonal antibodies from Cayman Chemicals (Ann Arbor, MI) were used, as described previously (25, 45) . For A3AR expression, rabbit polyclonal A3 antiserum was used as described earlier by Feoktistov et al. (12) .
Aliquots of the aortic tissues (40 g protein/well) were separated on 10% SDS-PAGE. Prestained low-range marker (Bio Rad cat. no. 161-0305) was run parallel. Proteins were transferred onto nitrocellulose membrane and probed with anti-A3AR at 1:1,000, anti-COX-1 and -TP receptor antibodies at 1:200 dilutions, followed by incubation with secondary antibodies for 1 h (horseradish peroxidase-conjugated goat anti-mouse 1:5,000 dilution for COX-1; goat anti-rabbit 1:10,000 dilution for TP receptor and A3AR). After extensive washing, membranes were then stripped and reprobed with monoclonal anti-␤-actin antibody. For detection of bands, the membranes were treated with enhanced chemiluminescence (ECL) reagent (Amersham Biosciences) for 1 min and subsequently exposed to ECL Hyperfilm. Relative band intensities were quantified by densitometry (Alpha Innotech, San Leandro, CA). Western blot values are expressed as percentage of control after densitometric analysis.
Drugs used. Acetylcholine and PE were dissolved in distilled water. 
were dissolved in 100% DMSO, 5-(3-pyridynilmethyl)-2-benzofurancarboxylic acid (furegrelate) was dissolved in water, whereas indomethacin was dissolved in 100% ethanol as a 10 mM stock solution. The final concentration of the diluent in organ bath (10 ml) had no effect by itself on the aortic rings (1). All other chemicals and monoclonal anti-␤-actin were purchased from Sigma Chemical (St. Louis, MO) and were of the highest grade.
Data analysis. All of the experimental values are presented as means Ϯ SE (n ϭ number of animals). The comparison among different groups was analyzed by ANOVA followed by Tukey's method as a post hoc test. Comparison between two groups was assessed by unpaired t-test. P Ͻ 0.05 was taken as significant. EC 50 for aortic contraction was obtained by graphic analysis from individual curves by nonlinear regression (curve-fit) analysis. For quantification of TxB 2 level, a standard curve using TxB2 was run along with aortic samples. For the standard curve, the ratio of absorbance of bound ligand (TxB 2) to the absorbance of total binding was plotted against the log of the concentration of TxB2, and linear regression was performed to determine TxB2 levels in aortic samples. All of the statistical analyses were performed using Graph Pad Prism statistical package (version 3.0).
RESULTS

Concentration-dependent effect of Cl-IBMECA in WT/A 3 KO
ϩE/ϪE mice aorta. Incubation of WT aortic rings ϩE to increasing concentration of Cl-IBMECA enhanced the contraction in a concentration-dependent manner with an EC 50 ϭ 2.9 Ϯ 0.2 ϫ 10 Ϫ9 M (Fig. 1) . Cl-IBMECA (10 Ϫ7 M) increased contraction significantly by 29% in ϩE, while producing negligible effect (Ϸ6%) in endothelium-denuded (ϪE) WT mouse aorta, whereas these results were insignificant for both ϩE and ϪE A 3 KO mouse aorta. The Cl-IBMECA (10 Ϫ7 M)-induced contraction in WT ϩE aorta was completely abolished by MRS 1523 (10 Ϫ5 M), a specific A 3 AR antagonist.
These results suggest that A 3 AR-mediated contraction is dependent on functional endothelium in mice aorta. Fig. 2A , in WT ϪE aorta, A 3 AR gene expression decreased significantly (74%) compared with WT ϩE aorta, whereas this expression was undetected in A 3 KO ϩE/ϪE aorta.
The presence of A 3 AR protein in the ϩE/ϪE aorta of WT and A 3 KO mice was detected with rabbit polyclonal A 3 antiserum. As can be seen in Fig. 2B , Western blot analysis showed a decrease in A 3 AR protein expression by 72% in WT ϪE aorta compared with WT ϩE aorta. A 3 AR protein expression was undetected both in A 3 KO ϪE and ϩE aorta. These results demonstrate the presence of A 3 AR expression, mostly on the endothelium of WT mice aorta. (Fig.  4B) . In a separate experiment, addition of SC-560 (10 Ϫ8 M) and NS-398 (10 Ϫ6 M) together abolished completely the Cl-IBMECA-induced contraction in this tissue WT ϩE (data not shown). These data suggest that COX-1 is mainly involved in A 3 AR-mediated endothelium-dependent contraction in WT mice aorta. Therefore, further studies were conducted to support the involvement of COX-1 pathway in A 3 AR contraction in this tissue. Figure 5A shows COX-1 gene expression in WT and A 3 KO ϩE/ϪE aorta. COX-1 gene expression decreased significantly by 96% (P Ͻ 0.05) in WT ϪE compared with WT ϩE aorta. In A 3 KO ϪE aorta, COX-1 gene expression also decreased significantly by 85% (P Ͻ 0.05) compared with A 3 KO ϩE aorta. These data were further confirmed by Western blotting using COX-1 antibody (Fig.  5B) . Densitometric analysis showed that COX-1 expression in WT ϪE aorta decreased by 94% (P Ͻ 0.05) compared with WT ϩE aorta, whereas in A 3 KO ϪE aorta, this expression decreased by 82% (P Ͻ 0.05) compared with A 3 KO ϩE aorta. These data suggest that the COX-1 gene is mainly expressed on the aortic endothelium of WT/A 3 KO mice. 3 KO ϩE mice aorta. The purpose of this experiment was to determine whether Cl-IBMECA-induced contraction is mediated through upregulation of COX-1. As can be seen in Fig. 6 , left, the densitometric analysis of Western blot shows the increased COX-1 expression in the presence of Cl-IBMECA (10 Ϫ7 M) by 43% (P Ͻ 0.05) over untreated WT ϩE aorta (control, 100%). Pretreatment of aortic rings with MRS1523 (10 Ϫ5 M) before Cl-IBMECA almost completely reversed the Cl-IBMECA-induced increase in COX-1 expression in WT ϩE. Cl-IBMECA-induced COX-1 expression was insignificant in A 3 KO ϩE aorta (Fig. 6, right) . 3 KO ϩE mice aorta. This experiment was conducted to gain further insight into the possible participation of vasoconstrictive prostanoids generated by COX-1 metabolism after activation of A 3 AR with the use of TP receptor antagonist (SQ 29548). SQ 29548 (10 Ϫ6 M) significantly inhibited the CRC produced by Cl-IBMECA in WT ϩE aorta. The contractile response produced by Cl-IBMECA at 10 Ϫ7 M was reduced by 60.3% (P Ͻ 0.05) in the presence of SQ 29548 (10 Ϫ6 M) in WT ϩE, whereas this effect was insignificant in A 3 KO ϩE aorta (Fig. 7) . These results demonstrate that end products of COX-1 metabolism play an important role in A 3 AR-induced contraction in this tissue.
Effects of indomethacin (a nonspecific COX blocker) on Cl-IBMECA-induced contraction in WT/
COX-1 gene expression by real-time PCR and Western blot in WT/A 3 KO ϩE/ϪE mice aorta.
Effect of Cl-IBMECA on COX-1 expression by Western blotting in WT/A
Inhibition of Cl-IBMECA-induced contraction by TP receptor antagonist SQ 29548 in WT/A
Effect of TS inhibitor furegrelate on Cl-IBMECA-induced contraction.
To further demonstrate involvement of TS in A 3 AR-mediated contraction in mice aorta, we used the TS inhibitor furegrelate on Cl-IBMECA-induced contraction. Furegrelate (10 Ϫ5 M) inhibited Cl-IBMECA (10 Ϫ7 M)-induced contraction by 61% (Fig. 8) in WT ϩE mice aorta, whereas it produced no effects in A 3 KO mice aorta. These results demonstrate the involvement of Tx in A 3 AR-mediated contraction in mice aorta. 
Effect of furegrelate on Cl-IBMECA-induced TP receptor expression in WT ϩE mice aorta. The effect of furegrelate on
Cl-IBMECA (10 Ϫ7 M)-induced TP receptor expression was also determined. Figure 9 shows representative immunoblots of TP receptor expression with densitometric analysis. As can be seen from Fig. 9 , the treatment of WT ϩE aortic rings with Cl-IBMECA for 60 min resulted in a 62% increase in TP receptor expression compared with untreated control. Cl-IBMECA-induced increase in TP receptor expression was markedly attenuated by preincubation of WT ϩE aortic rings for 30 min with furegrelate (10 Ϫ5 M) and MRS1523 (10 Ϫ5 M). These results demonstrate that A 3 AR activation is linked to the upregulation of TP receptor, probably via activation of TS. Table 1 , the TxB 2 (a stable TxA 2 metabolite) levels increased by 71% with Cl-IBMECA treatment alone in WT ϩE aorta compared with untreated control. The Cl-IBMECA-induced increase in TxB 2 levels were attenuated significantly in the presence of indomethacin (10 Ϫ5 M), SC-560 (10 Ϫ8 M), and furegrelate (10 Ϫ5 M) ( Table 1) . TxB 2 levels were unaffected by A 3 AR agonist (Cl-IBMECA) or COXs, COX-1, and TS blockers (indomethacin, SC-560, and furegrelate) in A 3 KO ϩE mice aorta (Table 1 ). These data suggest that major metabolite of COX-1 pathway could be TxB 2 in A 3 AR-mediated contraction. Removal of endothelium ϪE in WT mice aorta resulted in a 63% reduction in TxB 2 levels compared with untreated control (data not shown), which further supports our molecular and organ bath data that A 3 AR-COX-1 signaling may be mediated through endothelium.
Measurement of TxB 2 levels in the presence of COX blockers and TS inhibitor. As shown in
DISCUSSION
In the present study, we have investigated A 3 AR-mediated endothelium-dependent contraction in relation to COX signaling pathway using WT/A 3 KO mice aorta. Our findings showed that the activation of A 3 AR by selective agonist Cl-IBMECA led to contraction and increase in TxB 2 production in WT mice aorta that was dependent on the integrity of endothelium, since this response was almost completely abolished after removal of functional endothelium. This was also confirmed by real-time PCR and Western blot data that showed the presence of A 3 AR expression, mostly on aortic endothelium. Furthermore, our data showed that A 3 AR-mediated contraction in WT aorta is dependent mainly on endothelial COX-1, which was also confirmed by real-time PCR and Western blot data. COX-1 gene expression was significantly induced by A 3 AR activation in WT ϩE aorta, whereas this increase in expression was negligible in A 3 KO. Activation of A 3 AR also resulted in increased TP receptor activation that was attenuated by furegrelate (TS inhibitor). Cl-IBMECA-induced increase in COX-1 and TP receptor expression was markedly attenuated by MRS1523, a specific A 3 AR antagonist in WT ϩE aorta. Nonspecific COX blocker, COX-1 specific blocker, and TS inhibitor also attenuated Cl-IBMECA-induced increase in TxB 2 levels. Furthermore, contractile response to A 3 AR agonist and inhibitory effects produced by COX blockers were absent in A 3 KO ϩE and ϪE aorta.
Our data demonstrated that Cl-IBMECA, a specific A 3 AR agonist, produced a concentration-dependent contraction in WT ϩE mice aorta, which was completely abolished by its specific antagonist (MRS 1523). The contractile response was specific to A 3 AR activation, as it was confirmed by the use of the selective A 1 AR agonist (CCPA). The CCPA-induced aortic contraction was not affected by MRS 1523, while this effect was blocked by A 1 AR antagonist (DPCPX, data not shown). The antagonists for A 3 AR (MRS 1523) and A 1 AR (DPCPX) have been used previously in our laboratory (11, 36) . Taken together, these findings suggest that Cl-IBMECA-induced contraction of aortic rings was primarily due to activation of A 3 AR and not due to the activation of A 1 AR in this tissue. Shepherd et al. (30) have previously reported the involvement of A 3 ARmediated vasoconstriction in hamster arterioles in vivo, which supports our present data. However, these authors did not address the role of endothelium in A 3 AR-mediated vasoconstriction (30) .
In support of our hypothesis that A 3 AR-mediated contraction is dependent on the integrity of endothelium, our data showed that the removal of endothelium in WT aorta resulted in the loss of contractile response to Cl-IBMECA. As further evidence that A 3 AR is indeed expressed on endothelium, we measured the gene expression in WT/A 3 KO ϩE/ϪE aorta by real-time PCR and protein expression by Western blot analysis. The WT ϪE aorta showed a significant decrease in A 3 AR expression compared with WT ϩE aorta, whereas A 3 KO ϩE/ϪE showed undetected levels of A 3 AR expression. A 3 AR expression in different vascular tissues has also been reported by other workers (43, 44) . Recently, Zhao et al. (43) reported that the blood pressure in A 3 KO mice was similar to that in WT mice; however, when given adenosine infusion (intravenously), A 3 KO mice displayed a significant decrease in blood pressure compared with WT mice. The fall in blood pressure in A 3 KO mice could be due to the absence of the release of endothelium-derived contractile mediators, which may be present in WT mice (43) . Overall, our findings demonstrate that A 3 AR-mediated contraction in WT aorta is dependent on endothelium, which might play an important role in the regulation of blood pressure. The endothelium-derived contracting factors include superoxide and/or PGH 2 /TxA 2 generated by COX-mediated metabolism of arachidonic acid (2, 13, 21, 31, 40) . Pretreatment of aortic rings with a nonspecific COX blocker (indomethacin) and specific COX-1 blocker (SC-560) resulted in inhibition of Cl-IBMECA-induced contraction, whereas COX-2 blocker (NS-398) showed an insignificant inhibitory effect in WT ϩE mice aorta. The findings in the present study, that SC-560 inhibited Cl-IBMECA-induced contractions almost completely compared with NS-398, indicate that vasoconstriction is mediated mainly through COX-1 in this tissue. These findings are further supported by the observation that pretreatment of WT ϩE aortic rings with indomethacin, SC-560, and furegrelate significantly inhibited TxB 2 levels compared with Cl-IBMECA alone (Table 1 ). An earlier report has also shown that COX-1 predominantly contributes to basal PG production, because COX-1 inhibitors significantly decrease total PG products in both kidney and aorta (27) . Heymes et al. (20) have also demonstrated COX-1 as the major isoform of COXs in rat aorta. Our findings correlate with the above reports, suggesting that COX-1 is mostly involved in A 3 AR-mediated contraction.
Further studies were carried out to confirm the location and involvement of COX-1 in A 3 AR-mediated contraction. COX-1 expression was located mainly on the endothelium, as its removal led to significant decreases in both gene and protein expression of COX-1. Treatment of WT ϩE aorta with Cl-IBMECA resulted in upregulation of COX-1 expression, while producing a negligible effect in A 3 KO. Cl-IBMECA-induced increase in COX-1 expression was significantly blocked by MRS1523, a specific A 3 AR antagonist in WT ϩE aorta. These data corroborate organ bath experiments and show that COX-1-mediated contraction after A 3 AR activation in WT ϩE aorta may also require functional endothelium. Previous reports have also shown the expression of COXs on aortic endothelium of different species, which support our present studies (23, 24, 33) .
The observations that COX-1 and COX-2 blockers produce different responses to Cl-IBMECA-induced contraction in pharmacological studies suggest that these isoforms are regulated differentially after A 3 AR activation in the mice aorta. Clinical and animal studies also show that COX-1 and COX-2 are regulated differentially in the production of total prostanoids in both the renal and cardiovascular system (4, 26, 34, 42) . The differential regulation could be due to the fact that COX-1, being a constitutive enzyme, plays an important role in the basal production of prostanoids and Tx (3, 9, 10, 19, 27) , whereas COX-2, being an inducible enzyme, plays a significant role under inflammatory/disease conditions (7, 33) . Additional studies on disease models are needed to further explore our understanding in this area of research.
We further confirmed the involvement of end products of COX metabolism in A 3 AR-mediated contractions by using TP receptor antagonist (SQ 29548), COX blockers (indomethacin, SC-560), and TS inhibitor (furegrelate). SQ 29548 inhibited Cl-IBMECA-mediated contractions to a similar degree, as shown by nonspecific COX blocker (indomethacin) and by specific COX-1 blocker (SC-560), thus demonstrating that COX-1 is indeed involved in A 3 AR-mediated aortic contraction. A 3 AR-mediated contraction and increase in TP receptor expression were markedly reduced by pretreatment with furegrelate, as well as MRS1523, a specific A 3 AR antagonist. Furthermore, one of major end metabolites of COX pathway, i.e., TxB 2 , was found to be increased after activation of A 3 AR with Cl-IBMECA, which was decreased by pretreatment with COX/COX-1 blockers and TS inhibitor (Table 1) . These findings strongly suggest the involvement of A 3 AR-COX-1-TxA 2 pathway in aortic contraction via endothelium.
In conclusion, the present study demonstrated for the first time, utilizing WT and A 3 KO mouse aorta, that 1) activation of A 3 AR in WT leads to contraction, mainly via endothelium; and 2) A 3 AR-mediated contraction and TxB 2 production are dependent mainly on COX-1 signaling pathway. Finally, our studies suggest that the A 3 AR-mediated contraction through endothelium may play a role in cardiovascular inflammation, including hypertension and atherosclerosis, by affecting COX signaling pathways. This could play an important role in the pathophysiology of vascular diseases and could provide newer therapeutic approaches.
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